#AceHealthReport – May.07: The Oxford/AstraZeneca vaccine is safe, effective and has already saved thousands of lives in the UK and around the world.
#CoronavirusNewsDesk Statement on AstraZeneca #COVID19 vaccine following JCVI update: The government’s statement following updated advice from the Joint Committee on Vaccination and Immunisation (JCVI)’
As the MHRA – the UK’s independent regulator – and the Joint Committee on Vaccination and Immunisation have said, the benefits of the vaccine far outweigh the risks for the vast majority of adults.
The government will follow today’s updated advice, which sets out that, as a precaution, it is preferable for people under the age of 40 with no underlying health conditions to be offered an alternative vaccine where possible once they are eligible, and only if doing so does not cause a substantial delay in accessing a vaccination.
More than 50 million vaccines overall have already been administered, and our current vaccine supply and rate of infection means we are able to take this precautionary step while remaining on track to achieve our target of offering a vaccine to all adults by the end of July.
Everybody who has already had a first dose of the Oxford/AstraZeneca vaccine should receive a second dose of the same jab, irrespective of age, except for the very small number of people who experienced blood clots with low platelet counts following their first vaccination.
When people are called forward, they should get their jab. Vaccines are the best way out of this pandemic and provide strong protection against COVID-19.
#CoronavirusNewsDesk – New study finds strong immune response following #COVID19 vaccination: ‘Study led by Sheffield and Oxford Universities finds that 99% of people have robust immune response against COVID-19 after one dose of Pfizer vaccine’
237 healthcare workers tested for antibody and T cell responses, as part of the largest and most in-depth study on the immune response following COVID-19 vaccination
First findings from DHSC-funded PITCH study shows one dose of the Pfizer vaccine generates robust T cell and antibody responses in 99% of people
Study shows people who have previously had COVID-19 generate stronger T cell and antibody responses following one dose of the Pfizer vaccine
A new study led by Sheffield and Oxford Universities with support from the UK Coronavirus Immunology Consortium has found that 99% of people generate a robust immune response against COVID-19 after just one dose of the Pfizer vaccine.
The Protective Immunity from T cells to COVID-19 in health workers study (PITCH) examined how the immune system responds to COVID-19 after one dose of the Pfizer vaccine among people who have been infected by COVID-19 before and those who have not.
It suggests one dose of the vaccine protects against severe disease, supporting the decision to delay the second dose and provide protection to as many higher-risk groups as possible by providing more first doses. The study showed after 2 doses levels of protection were even stronger, underlining the importance of people coming forward for their second dose.
Between 9 December 2020 and 9 February 2021, researchers from the Universities of Sheffield, Oxford, Liverpool, Newcastle and Birmingham analysed blood samples from 237 healthcare workers to understand their T cell and antibody responses following vaccination from the Pfizer vaccine.
The study also sheds light on the impact of previous infection from COVID-19 on people’s immune response to vaccination. It found people who had previously been infected with COVID-19 showed higher T cell and antibody responses after one dose of the Pfizer vaccine compared with people who had never had COVID-19 before and had one dose of the vaccine.
The researchers discovered that among people who had had COVID-19 in the past, the T cell response expanded after vaccination to recognise more regions of the COVID-19 spike protein – which attacks the immune system and causes severe disease. This means, even in those already infected, vaccination from the Pfizer jab provides better protection and an enhanced immune response to COVID-19 than the immune response from natural infection.
It is not yet known how long T cell and antibody response lasts following infection. The first dose of both the Pfizer and AstraZeneca vaccine offer good levels of protection, but to get maximum protection it is vital everyone gets a second dose when invited as 2 doses of the vaccine will provide longer-lasting protection from the virus.
Health and Social Care Secretary Matt Hancock said:
The PITCH study presents further proof that vaccines provide excellent protection against the virus. Thanks to the incredible efforts of our vaccination programme, over half of all adults in the UK have had the jab, and we remain on track to offer all adults a vaccine by the end of July.
A second vaccine jab is crucial for longer-term protection, regardless of whether you have previously had COVID-19 or not, and I urge everyone to make sure they attend their second appointment – to keep themselves and those around them safe.
Health Minister Lord Bethell said:
These findings from the PITCH study are crucial to increasing our understanding of the immune response to COVID-19 and how the Pfizer vaccine is working to protect people across the UK already.
I urge everyone to come forward to be vaccinated when invited and to take up both doses of the vaccine as both are vital to ensuring long-term protection from COVID-19.
Key findings from the PITCH study
Among individuals who had not had COVID-19 in the past and had received 2 doses of the Pfizer vaccine, T cell response was as strong as people who had had previous COVID-19 infection and one vaccine dose.
After one dose of the Pfizer vaccine, individuals who had previous COVID-19 infection showed higher antibody and T cell responses compared with people who had not been infected before. Antibody responses were 6.8 times higher and T cell responses 5.9 times higher.
Among individuals who had not had COVID-19 in the past and had received one dose of the Pfizer vaccine, antibody and T cell responses were at a similar or higher level compared to those who had previously been infected but not been vaccinated.
There was a 10-fold greater spike-specific T cell responses following vaccination in people with previous infection compared to those who had no prior infection.
There was no link between age and levels of T cell/antibody response.
An effective vaccine is one that that saves lives and reduces hospitalisations. Both the Pfizer and Oxford-AstraZeneca vaccines have been shown to be highly effective in reducing COVID-19 infections among older people aged 70 years, according to previously published research carried out by Public Health England. In the over 80s, data suggest that a single dose of either vaccine is more than 80% effective at preventing hospitalisation, around 3 to 4 weeks after the jab.
Further research will continue to deepen our understanding of the immune responses over the longer term and what it means for protection against COVID-19 in the real world.
Even after vaccination everyone must continue to follow the rules – remembering Hands, Face, Space – as it may still be possible to pass the virus on to others after having the jab.
Dr Thushan de Silva, study author from the University of Sheffield, said:
Our study is one of the largest and most comprehensive accounts of the immune response to one dose of Pfizer/BioNTech vaccine comparing previously infected and infection-naive individuals. Our results demonstrate that T cell and antibody responses induced by natural infection are boosted significantly by a single dose of vaccine. While the response to a single dose was lower in infection-naïve individuals, it was still equivalent or better than the immunity in previously infected individuals before it is boosted by vaccination.
Professor Susanna Dunachie, PITCH study lead from the University of Oxford, said:
Our study highlights the importance of studying both aspects of immune protection when trying to understand the underlying mechanisms of the immune response to COVID-19 vaccination. Interestingly, we also found that vaccination improves the breadth of T cell responses generated in previously infected individuals. In immunology, this is a good thing as it means that you are more likely to maintain protection against new mutations of the virus, and further work will assess how long these vaccine responses last. It’s still important that everyone follows NHS guidelines to get 2 doses of the vaccine, even if you think you may have previously had COVID-19.
The PITCH study has been a great opportunity to work collaboratively across 5 university hospitals and with Public Health England to look at T cell responses to SARS-CoV-2 at greater scale and depth than a single research centre can. By building on the national SIREN Study and putting our heads together, we are contributing towards illuminating the role of T cells in protection against COVID-19 from vaccines and previous infection.
Professor Paul Klenerman, PITCH study lead from the University of Oxford, said:
T cells are an important component of immunity to viruses – but typically much harder to measure than antibodies. To set this up at scale across the UK in the midst of a pandemic was a big challenge but the very clear data found by PITCH show just how informative this approach can be.
Of the 237 healthcare workers, 113 had previously been infected with COVID-19 compared to 124 healthcare workers who had not. For those who had not previously had COVID-19, 103 were given one dose of the vaccine and 21 were given 2 doses, with a gap of 23 days between doses. The researchers took blood samples from participants prior to and 28 days after vaccination to measure various aspects of the immune response, including antibodies and T cells.
A range of analyses were used to examine aspects of the T cell response including the magnitude of response and the response to different proteins from SARS-CoV-2. Carrying out these T cell analyses is much more complex than antibody studies and difficult to undertake at scale – but this study is the largest and most in depth in the world to date in this field.
Polack et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine 2020; 383(27): 2603-15.
Hall et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. medRxiv 2021: 2021.01.13.21249642.
#AceHealthReport – Mar.25: Pressure is growing on the European Commission and EU member states to reconsider their staunch opposition to measures that could open the possibility of a massive increase in #Covid19 vaccine production worldwide.
#CoronavirusNewsDesk – The EU Should Stop Blocking Efforts to Increase Global Vaccine Access: European Lawmakers Join Push for Waiving Intellectual Property Rules for #Covid19 Response: https://t.me/reuters_news_agency/69546 Reuters Wire News, [Mar 24, 2021 at 6:18 PM] UK and EU say looking to create ‘win-win’ situation on COVID-19 vaccines
LONDON (Reuters) – Britain and the European Commission said they are discussing how they can work together to create a “win-win” situation on COVID-19 vaccines after the bloc threatened to take tougher measures to curb the export of deliveries of shots: The European Commission has threatened to ban exports to countries like Britain that have higher vaccination rates but do not export shots to the EU. The aim is to safeguard supplies for the bloc’s own citizens as they face a third wave of the pandemic.: Given our interdependencies, we are working on specific steps we can take – in the short-, medium- and long term – to create a win-win situation and expand vaccine supply for all our citizens,” they said in a joint statement: In the end, openness and global cooperation of all countries will be key to finally overcome this pandemic and ensure better preparation for meeting future challenges. We will continue our discussions.”
The proposal would facilitate technology transfers so that Covid-19 medical products, including vaccines, could be produced quickly and affordably by manufacturers around the world, in line with a rights-based approach to the pandemic and growing calls for a “peoples’ vaccine” freely available to all.
As EU heads of state prepare to discuss the bloc’s response to the pandemic later this week, they should heed the calls coming from elected representatives and citizens and reconsider their opposition to the intellectual property waiver. As European lawmakers put it, “we will not defeat the virus until we defeat it everywhere.” And with new strains emerging all the time, we will hardly defeat it anywhere without a mass global vaccine rollout. The pandemic has already had an enormous human and economic cost. European leaders should stop standing in the way of a measure that could accelerate and increase global vaccine production and availability and bring us closer to ending the pandemic.
#AceHealthReport – Mar.21: The European Union could stop AstraZeneca from exporting its COVID-19 vaccine from the bloc if the British-Swedish pharma company does not meet its supply obligations, European Commission President Ursula von der Leyen said in comments published on Saturday.
‘EU warns AstraZeneca of export ban if bloc not supplied first: European Commission head Ursula von der Leyen has upped the pressure on pharma company AstraZeneca, threatening to forbid planned exports until the firm fulfils its obligations to Europe in comments on Saturday’
“We have the possibility to forbid planned exports. That is the message to AstraZeneca: You fulfill your contract with Europe before you start delivering to other countries,” von der Leyen told newspapers from the Funke Media Group.
She said the company had delivered only 30% of the doses promised in the first quarter of 2021. She also pointed out that although the contract with AstraZeneca had stipulated that the EU would receive vaccines from factories in the EU and Britain, “we have received nothing from the Britons, while we deliver vaccines to them.”
Despite the confidence exuded by von der Leyen here, the EU is having grave problems with its vaccination drive.
Von der Leyen referred to statistics showing that at least 41 million doses of coronavirus vaccine had been exported from the EU to 33 countries, despite a shortfall in vaccine supplies in the bloc itself. According to the commission, 9 million doses have gone from the EU to the UK and a million to the US.
“I cannot justify to European citizens why we export millions of vaccine doses to countries that produce vaccines themselves — and from whom nothing comes back,” von der Leyen said. “And I can barely justify exports to countries that have a much higher vaccination rate and far fewer infections than the EU.”
She called on other countries to reciprocate the EU’s openness and said the bloc was inviting national leaders for discussion.
Vaccination programs in the EU, including Germany, have been comparatively slow in getting underway, partly because of a lack of doses.
AceNewsServices – FLORIDA – Nov.11 – Sure, vaccines are safe — except when they randomly trigger extreme brain inflammation that leads to vision loss, paralysis and an inability to speak.
This is what happened to now-10-year-old Marysue Grivna of Tampa, Florida, just four days after she received a flu vaccine, which left her completely debilitated with a serious brain disease known as acute disseminated encephalomyelitis, or ADEM.
It all began on November 22, 2013, when young Marysue was taken in to get a seasonal flu vaccine. Just days later, the child began to get sick and quickly developed symptoms of paralysis.
Worried, her parents took her in for an evaluation and it was determined that she had succumbed to an immune disorder caused by inflammation of the brain.
Similar to multiple sclerosis, ADEM manifests as an autoimmune disorder in which the body attacks itself, in this case targeting the protective coverings surrounding nerve fibres. Known as myelin, these coverings are meant to protect nerves in the brain and spinal cord, for instance, from being harmed. In their absence, symptoms like loss of vision and paralysis can occur.
“Her father Steven and I are certain, due to all our research, that this was what caused Marysue’s condition,” stated the girl’s mother, Carla, during a recent interview with Fox & Friends. “The doctors won’t confirm it or deny it… [but] she was a happy, healthy, running, and playing nine-year-old.
“Regrettably, the vaccine against the Nazi virus developed at the Nuremberg trials is losing its efficiency in some European state,” Putin said in an interview with Serbia’s daily newspaper Politika on Tuesday.
#AceHealthNews – SAUDI ARABIA – April 13 – (ALJ) – A foreigner has died from the deadly MERS coronavirus in Saudi Arabia, while Yemen has reported its first case of the disease.
The foreign man, whose nationality has not been disclosed, died from the coronavirus as eight others in the kingdom, including five health workers in the city of Jeddah, were infected.
The death brings the nationwide toll in the world’s most-affected country to 68, with 189 people infected.
The Saudi health ministry, which announced the death, said five health workers – two women and three men – and three other people had been infected by MERS in Jeddah.
The announcement came days after panic over the spread of the virus among medical staff led to the closure of the emergency room at the city’s main public hospital.
The World Health Organisation (WHO) on Friday said that it had been told of 212 laboratory-confirmed cases of MERS infection worldwide, of which 88 were fatal.
MERS is considered a deadlier but less-transmissible cousin of the SARS virus that erupted in Asia in 2003 and infected 8,273 people, nine percent of whom died.
Experts are still struggling to understand MERS, for which there is no known vaccine.
A study has said the virus has been “extraordinarily common” in camels for at least 20 years, and may have been passed directly from the animals to humans.
The UAE news agency WAM said on Friday an expatriate health worker had died from the virus and five others had been infected in the Gulf state. This followed Saudi reports last week of two deaths and nine other cases of infection in the kingdom, including among hospital staff.
The mainstream media has utterly abandoned science in the push for more flu shot propaganda, entirely failing to mention any of the risks associated with vaccines. According to nearly every story published in the mainstream media, flu shot vaccines offer almost certain protection against the flu while carrying absolute zero risk (risk is never mentioned).
This is why vaccines routinely cause seizures in children, fevers, vomiting, comas and even death. The risk of this becoming known to the public is so great that a private, unconstitutional court called the “vaccine court” was established in order to pay off parents of vaccine-damaged children while requiring them to sign non-disclosure agreements to force them into silence. (Click here to see the astonishing video revealing this.)
Media stories that don’t mention flu shot risks are irresponsible and may cause harm to the public
Any media source that publishes an article pushing flu shots without offering a reasonable discussion of the inherent risk from doing so is acting in a highly irresponsible manner, potentially putting millions of children in harm’s way. Yet mainstream media journalists routinely fail to discuss any risks whatsoever of vaccines, almost as if such risks did not exist.
These journalists are either scientifically illiterate and not aware of such risks, or they are actively deciding to censor such discussions from their stories, thereby conspiring with the vaccine industry to keep the public ignorant of a medical intervention which may cause them serious harm or death. Such actions are highly unethical and smack of a complete lack of journalistic professionalism.
Watch the new Health Ranger video explanation
To learn more about flu shot propaganda, media lies and the abandonment of real science by the vaccine industry, watch this new screen cast video I just posted: